The usage of thiotriazolin in complex treatment of patients with community acquired pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 579s Year: 2005
The usage of laferon in treatment of patients with community acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007
Improving outcome in elderly patients with pneumonia Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005
Hospital-acquired pneumonia in patients receiving immunosuppressive therapy Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009
Therapeutic regimens in community acquired pneumonia (CAP): association with patients characteristics and outcomes Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
The general evaluation of community acquired pneumonia patients treated in our clinic Source: Eur Respir J 2004; 24: Suppl. 48, 414s Year: 2004
Switching of antimicrobial agents in the therapy of community acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009
The efficiency of levofloxacin in the therapy of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 5s Year: 2006
The general evaluation of elderly patients with community acquired pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 412s Year: 2004
Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Cytokine-based prediction of aetiology in community acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017
Cost-efficacy analysis of cefixime switch therapy in the treatment of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
Influence of medical comorbidities in patients with community acquired pneumonia Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010
Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning Source: Eur Respir J, 54 (6) 1900824; 10.1183/13993003.00824-2019 Year: 2019
Effectiveness of empirical treatment of community acquired pneumonia requiring hospitalization Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006
Influence on the prognosis of misuse of antibiotics prior to admission in patients with community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
How often can we use short course therapy in patients with hospital-acquired pneumonia? Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007
Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008
Evaluation of clinical efficiency of thiotriazolin in complex treatment of patients with community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007